Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom
Open Access
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 31 (8), 1535-1544
- https://doi.org/10.1007/s00198-020-05358-4
Abstract
This paper demonstrates a large post-fracture anti-osteoporosis treatment gap in the period 2005 to 2015. The gap was stable in Denmark at around 88-90%, increased in Catalonia from 80 to 88%, and started to increase in the UK towards the end of our study. Improved post-fracture care is needed. Introduction Patients experiencing a fragility fracture are at high risk of subsequent fractures, particularly within the first 2 years after the fracture. Previous studies have demonstrated that only a small proportion of fracture patients initiate therapy with an anti-osteoporotic medication (AOM), despite the proven fracture risk reduction of such therapies. The aim of this paper is to evaluate the changes in this post-fracture treatment gap across three different countries from 2005 to 2015. Methods This analysis, which is part of a multinational cohort study, included men and women, aged 50 years or older, sustaining a first incident fragility fracture. Using routinely collected patient data from three administrative health databases covering Catalonia, Denmark, and the United Kingdom, we estimated the treatment gap as the proportion of patients not treated with AOM within 1 year of their first incident fracture. Results A total of 648,369 fracture patients were included. Mean age 70.2-78.9 years; 22.2-31.7% were men. In Denmark, the treatment gap was stable at approximately 88-90% throughout the 2005 to 2015 time period. In Catalonia, the treatment gap increased from 80 to 88%. In the UK, an initially decreasing treatment gap-though never smaller than 63%-was replaced by an increasing gap towards the end of our study. The gap was more pronounced in men than in women. Conclusion Despite repeated calls for improved secondary fracture prevention, an unacceptably large treatment gap remains, with time trends indicating that the problem may be getting worse in recent years.Funding Information
- UCB
This publication has 35 references indexed in Scilit:
- Closing the gap in postfracture care at the population level: a randomized controlled trialCMAJ : Canadian Medical Association Journal, 2011
- Clinical subsequent fractures cluster in time after first fracturesAnnals Of The Rheumatic Diseases, 2008
- Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEmergencias, 2008
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEmergencias, 2008
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEmergencias, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004
- The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal OsteoporosisThe New England Journal of Medicine, 2004
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2001
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000